Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer

Por Cortés-Funes, H, Mendiola, C, Manso, L, Ciruelos, E
Publicado no Breast Cancer Res (2009)

Circulating epithelial tumor cells in patients with metastatic breast cancer treated with bevacizumab

Por Manso, L, Ciruelos, E, Rodríguez, A, Diaz, J, Mendiola, C, López-Martín, JA, Cortes-Funes, H
Publicado no Breast Cancer Res (2009)

Lobular carcinoma of the breast: outcome of 205 patients

Por Vega, E, Ciruelos, E, Valdiviezo, N, Mendiola, C, Manso, L, Ghanem, I, Dorta, M, Pascual, T, Flores, C, Cortés-Funes, H
Publicado em 2011

Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracy...

Por Campone, M, Cortes-Funes, H, Vorobiof, D, Martin, M, Slabber, C F, Ciruelos, E, Bourbouloux, E, Mendiola, C, Delgado, F M, Colin, C, Aslanis, V, Fumoleau, P
Publicado em 2006

GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012

Por González Martín, A., Redondo, A., Jurado, M., De Juan, A., Romero, I., Bover, I., Del Campo, J. M., Cervantes, A., García, Y., López-Guerrero, J. A., Mendiola, C., Palacios, J., Rubio, M. J., Poveda Velasco, A.
Publicado em 2013